相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deep brain stimulation in Huntington's disease: Assessment of potential targets
Mayur Sharma et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
D. Angus et al.
LANCET NEUROLOGY (2015)
A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease
Ralf Reilmann et al.
MOVEMENT DISORDERS (2015)
Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease
Ana Silva et al.
NEURODEGENERATIVE DISEASES (2015)
Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease
Susanna Pietropaolo et al.
NEUROPHARMACOLOGY (2015)
4-Hydroxy Tempo Improves Mitochondrial and Neurobehavioral Deficits in Experimental Model of Huntington's Disease
Rajat Sandhir et al.
SYNAPSE (2015)
A Phase II, Open-Label Evaluation of Cysteamine Tolerability in Patients With Huntington's Disease
Adriana Prundean et al.
MOVEMENT DISORDERS (2015)
Mutant Huntingtin is Present in Neuronal Grafts in Huntington Disease Patients
Francesca Cicchetti et al.
ANNALS OF NEUROLOGY (2014)
The Role of Oxidative Stress in Huntington's Disease: Are Antioxidants Good Therapeutic Candidates?
Joana Gil-Mohapel et al.
CURRENT DRUG TARGETS (2014)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease
Gaynor A. Smith et al.
HUMAN MOLECULAR GENETICS (2014)
Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature
D. Gruber et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study
Victoria Gonzalez et al.
JOURNAL OF NEUROSURGERY (2014)
Results of the Citalopram to Enhance Cognition in Huntington Disease Trial
Leigh J. Beglinger et al.
MOVEMENT DISORDERS (2014)
Targets for Future Clinical Trials in Huntington's Disease: What's in the Pipeline?
Edward J. Wild et al.
MOVEMENT DISORDERS (2014)
Current Therapeutic Options for Huntington's Disease: Good Clinical Practice Versus Evidence-Based Approaches?
Annie Killoran et al.
MOVEMENT DISORDERS (2014)
PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Herminia D. Rosas et al.
NEUROLOGY (2014)
Bilateral Globus Pallidus Stimulation in Westphal Variant of Huntington Disease
Giuliana Cislaghi et al.
NEUROMODULATION (2014)
Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
Jens Niewoehner et al.
NEURON (2014)
Review: The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence
G. Cisbani et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
A 5-year follow-up of deep brain stimulation in Huntington's disease
Jose Luis Lopez-Sendon Moreno et al.
PARKINSONISM & RELATED DISORDERS (2014)
A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington's Disease
Daniel Todd et al.
PLOS ONE (2014)
Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons
Jun Tian et al.
NEUROSCIENCE BULLETIN (2014)
Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntingtons disease
Mali Jiang et al.
HUMAN MOLECULAR GENETICS (2013)
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
Roger A. Barker et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
A Small Molecule TrkB Ligand Reduces Motor Impairment and Neuropathology in R6/2 and BACHD Mouse Models of Huntington's Disease
Danielle A. Simmons et al.
JOURNAL OF NEUROSCIENCE (2013)
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline
Ralf Reilmann
MOVEMENT DISORDERS (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
DYSREGULATION OF SYNAPTIC PROTEINS, DENDRITIC SPINE ABNORMALITIES AND PATHOLOGICAL PLASTICITY OF SYNAPSES AS EXPERIENCE-DEPENDENT MEDIATORS OF COGNITIVE AND PSYCHIATRIC SYMPTOMS IN HUNTINGTON'S DISEASE
J. Nithianantharajah et al.
NEUROSCIENCE (2013)
Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease
Carmela Giampa et al.
PLOS ONE (2013)
Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review
Joe John Vattakatuchery et al.
WORLD JOURNAL OF PSYCHIATRY (2013)
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Wolfgang Brueck et al.
ACTA NEUROPATHOLOGICA (2012)
Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntingtons disease mice: implications for the ubiquitinproteasomal and autophagy systems
Haiqun Jia et al.
HUMAN MOLECULAR GENETICS (2012)
Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease
Jill Bouchard et al.
JOURNAL OF NEUROSCIENCE (2012)
P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease
Jing Fan et al.
NEUROBIOLOGY OF DISEASE (2012)
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease Report of the Guideline Development Subcommittee of the American Academy of Neurology
Melissa J. Armstrong et al.
NEUROLOGY (2012)
Targeting Neuro-Inflammatory Cytokines and Oxidative Stress by Minocycline Attenuates Quinolinic-Acid-Induced Huntington's Disease-Like Symptoms in Rats
Harikesh Kalonia et al.
NEUROTOXICITY RESEARCH (2012)
Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice
Alba Di Pardo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Mireia Garriga-Canut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
External globus pallidus stimulation modulates brain connectivity in Huntington's disease
Noemie Ligot et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2011)
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease
Denes Zadori et al.
JOURNAL OF NEURAL TRANSMISSION (2011)
Constitutive Upregulation of Chaperone-Mediated Autophagy in Huntington's Disease
Hiroshi Koga et al.
JOURNAL OF NEUROSCIENCE (2011)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
Daniela Berg et al.
MOVEMENT DISORDERS (2011)
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice
Danielle A. Simmons et al.
NEUROBIOLOGY OF DISEASE (2011)
Modulation of Mutant Huntingtin N-Terminal Cleavage and Its Effect on Aggregation and Cell Death
Katrin Juenemann et al.
NEUROTOXICITY RESEARCH (2011)
Dopamine and Glutamate in Huntington's Disease: A Balancing Act
Veronique M. Andre et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo
Justin Legleiter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice
Yuxiang Xie et al.
JOURNAL OF NEUROSCIENCE (2010)
A Futility Study of Minocycline in Huntington's Disease
Heidi Schwarz et al.
MOVEMENT DISORDERS (2010)
Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease
Carmela Giampa et al.
PLOS ONE (2010)
Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease
Youssef Sari et al.
JOURNAL OF BIOMEDICAL SCIENCE (2010)
Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies
S. Sarkar et al.
CELL DEATH AND DIFFERENTIATION (2009)
Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins
Ferdinando Squitieri et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Mutant huntingtin interacts with β-tubulin and disrupts vesicular transport and insulin secretion
Ruben Smith et al.
HUMAN MOLECULAR GENETICS (2009)
Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells
Tamara Ratovitski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease
Mary Y. Heng et al.
JOURNAL OF NEUROSCIENCE (2009)
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
Samuel Frank et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells -: Possible role of peroxisome proliferator-activated receptor-γ (PPARγ) in the pathogenesis of Huntington disease
Rodrigo A. Quintanilla et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Symptomatic treatment of Huntington disease
Octavian R. Adam et al.
NEUROTHERAPEUTICS (2008)
Transcriptional signatures in Huntington's disease
Jang-Ho J. Cha
PROGRESS IN NEUROBIOLOGY (2007)
Role of brain-derived neurotrophic factor in Huntington's disease
Chiara Zuccato et al.
PROGRESS IN NEUROBIOLOGY (2007)
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models
Dagmar E. Ehrnhoefer et al.
HUMAN MOLECULAR GENETICS (2006)
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase
M Borrell-Pagès et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells
ZK Mao et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Effect of fetal neural transplants inpatients with Huntington's disease 6 years after surgery:: a long-term follow-up study
AC Bachoud-Lévi et al.
LANCET NEUROLOGY (2006)
cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant huntingtin with expanded polyglutamine residues
MC Chiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Minocycline in phenotypic models of Huntington's disease
K Bantubungi et al.
NEUROBIOLOGY OF DISEASE (2005)
Paroxetine retards disease onset and progression in huntingtin mutant mice
WZ Duan et al.
ANNALS OF NEUROLOGY (2004)
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
M Tanaka et al.
NATURE MEDICINE (2004)
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease
J Schlefer et al.
BRAIN RESEARCH (2004)
Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach
DG Hay et al.
HUMAN MOLECULAR GENETICS (2004)
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
B Ravikumar et al.
NATURE GENETICS (2004)
Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease
RM Bonelli et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
C Zuccato et al.
SCIENCE (2001)
分享论文
